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Abstract
Background Many physicians consider platinum-doublet
chemotherapy inappropriate for elderly patients, regardless
of their medical fitness.
Objective This was a retrospective subgroup analysis of
data from a multicenter, randomized, phase III clinical trial
evaluating pemetrexed ? carboplatin versus doce-
taxel ? carboplatin in elderly chemo-naive patients with
advanced, nonsquamous non-small cell lung cancer
(NSCLC).
Methods Data from elderly patients (aged C65 years and
C70 years) were evaluated using the same statistical
methods as those used in patients aged \70 years and
qualified intent-to-treat (Q-ITT) populations. The primary
objective of the clinical trial was comparison of pemetr-
exed ? carboplatin with docetaxel ? carboplatin in terms
of survival without grade 3 or 4 toxicity in chemo-naive
NSCLC patients.
Results The C65- and C70-year age groups had 68 and
37 patients, respectively. Among patients aged C65 years,
the adjusted hazard ratio (HR) for survival without
grade 3–4 toxicity (HR 0.40, 95 % confidence interval [CI]
0.23–0.70) favored pemetrexed ? carboplatin; this was
similar to the HRs in patients aged C70 years (HR 0.43,
95 % CI 0.20–0.92), patients aged \70 years (HR 0.44,
95 % CI 0.32–0.62), and the Q-ITT population (HR 0.45,
95 % CI 0.34–0.61). The median values for overall sur-
vival (OS) and progression-free survival (PFS) were simi-
lar across all age-group subsets and the Q-ITT population.
The HRs for OS and PFS were similar for all age-group
subsets, except for the C70-year age group, which favored
pemetrexed ? carboplatin to a greater extent. The toxicity
profile was similar across age groups, with the exception of
diarrhea, mucosal inflammation, and grade 3–4 neutrope-
nia and leukopenia, which were slightly more common in
elderly patients in both treatment arms. Between-arm dif-
ferences in the toxicity profiles for the C65-, C70- and
\70-year age subgroups were similar to those in the Q-ITT
population. There were no on-study deaths or unexpected
toxicities.
Conclusion The benefits of pemetrexed ? carboplatin
were maintained, and toxicity was manageable in both
elderly subgroups. The favorable risk–benefit profile of
pemetrexed ? carboplatin makes it an appropriate first-
line treatment option for elderly patients with advanced
nonsquamous NSCLC.
1 Introduction
Lung cancer predominantly affects the elderly; the median
age of patients with non-small cell lung cancer (NSCLC) is
71 years [1]. Platinum-based doublets are the cornerstone
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of treatment for advanced NSCLC patients with a good
performance status. Although these produce a survival
benefit in elderly patients, only 30 % receive this treat-
ment, often because of physician concerns regarding
anticipated age-related toxicity.
To mitigate toxicity, alternative agents have been
incorporated into platinum-based backbones. Pemetr-
exed has been incorporated into first-line doublets [2–4],
and carboplatin has been used instead of cisplatin [5, 6].
In a phase III trial, pemetrexed ? carboplatin had a
more favorable risk–benefit ratio than docetaxel ? car-
boplatin [2]. This exploratory analysis evaluated the
efficacy and safety of pemetrexed ? carboplatin in
elderly patients.
2 Patient and Methods
This was a retrospective subset analysis of a phase III trial
comparing pemetrexed ? carboplatin and doce-
taxel ? carboplatin as first-line treatment in advanced
nonsquamous NSCLC [2]. Data from elderly patients were
evaluated in separate analyses (of patients aged C65 and
C70 years) from the analyses of 20- to \70-year-old
patients (i.e. patients aged \70 years).
Patients were administered the study drugs in an intra-
venous infusion on day 1 of each 21-day cycle, up to a
maximum of six cycles. Pemetrexed (500 mg/m2) or
docetaxel (75 mg/m2), and carboplatin (area under the
curve: 5 mg/mL 9 min) were administered. Patients in the
pemetrexed ? carboplatin group were supplemented with
at least five daily doses of oral folic acid (350–1,000 lg
once daily) within 7 days of the first dose of pemetrexed
and were required to take daily folic acid supplements for
21 days following treatment; an intramuscular injection of
vitamin B12 (1,000 lg) was given within 7 days of the first
dose of pemetrexed and once every three cycles thereafter;
and oral dexamethasone (4 mg twice daily) was required
the day before, the day of, and the day after administration
of pemetrexed [2]. Patients in the docetaxel ? carboplatin
group received supplementation with oral dexamethasone
(8 mg twice daily) the day before, the day of, and the day
after administration of docetaxel.
Time-to-event endpoints were analyzed using Cox pro-
portional hazard models adjusted for Eastern Cooperative
Oncology Group (ECOG) performance status (0 or 1 versus
2), disease stage (IIIB versus IV), ethnicity (East Asian
versus others), gender (male versus female), and smoking
status (never versus ever). The between-arm tumor
response and disease control rates were compared using
multivariate logistic regression models adjusted for the




The\70-, C65-, and C70-year age groups had 174, 68, and
37 patients, respectively, with median ages of 57.5, 70.3,
and 73.1 years, respectively. Between-arm imbalances in
the \70-, C65-, and C70-year age groups favored the
docetaxel ? carboplatin arm among women (pemetr-
exed ? carboplatin 39.3, 28.6, and 41.2 %, respectively,
versus docetaxel ? carboplatin 51.8, 51.5, and 55.0 %,
respectively) and never smokers (pemetrexed ? carbo-
platin 34.8, 14.3, and 17.6 %, respectively, versus doce-
taxel ? carboplatin 38.8, 33.3, and 40.0 %, respectively)
[Table 1].
3.1.1 Treatment Delivery
The six-cycle completion rates in the\70-, C65-, and C70-
year age groups were as follows: pemetrexed ? carbo-
platin 58.4, 57.1, and 52.9 %, respectively; doce-
taxel ? carboplatin 44.7, 54.5, and 60.0 %, respectively.
Among the qualified intent-to-treat (Q-ITT) population, the
six-cycle completion rates were pemetrexed ? carboplatin
57.5 % and docetaxel ? carboplatin 47.6 % [2]. Dose
reductions in the \70-, C65-, and C70-year age groups
were experienced by 9.0, 2.9, and 5.9 % of pemetr-
exed ? carboplatin-treated patients, respectively, and by
23.5, 39.4, and 40.0 % of docetaxel ? carboplatin-treated
patients, respectively; in the Q-ITT population, dose
reductions were experienced by 8.5 % of pemetr-
exed ? carboplatin-treated patients and by 26.7 % of
docetaxel ? carboplatin-treated patients [2]. All dose
reductions were due to adverse events (AEs). The median
relative dose intensities for pemetrexed ? carboplatin in
the\70-, C65-, and C70-year age groups were as follows:
pemetrexed 95.0, 95.4, and 95.5 %, respectively; carbo-
platin 92.4, 94.6, and 94.1 %, respectively; and those for
docetaxel ? carboplatin were as follows: docetaxel 96.4,
89.7, and 89.1 %, respectively; carboplatin 89.9, 84.4, and
82.9 %, respectively. Among Q-ITT patients, the median
relative dose intensities for pemetrexed ? carboplatin
were 95.3 % for pemetrexed and 92.7 % for carboplatin,
and those for docetaxel ? carboplatin were 95.0 % for
docetaxel and 88.7 % for carboplatin [2].
3.2 Survival Without Toxicity
Survival without grade 3 or 4 toxicity was significantly
improved in pemetrexed ? carboplatin-treated patients in
all age groups (Table 2). The adjusted hazard ratio (HR)
for the \70-year age group (median 3.4 months for
pemetrexed ? carboplatin versus 0.7 months for




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































292 J. R. Pereira et al.
docetaxel ? carboplatin; adjusted HR 0.44, 95 % con-
fidence interval [CI] 0.32–0.62; p \ 0.001) was consis-
tent with those in the C65-year age group (median
1.7 months for pemetrexed ? carboplatin versus
0.6 months for docetaxel ? carboplatin; adjusted
HR 0.40, 95 % CI 0.23–0.70; p = 0.002), the C70-year
age group (median 1.6 months for pemetrexed ? car-
boplatin versus 0.7 months for docetaxel ? carboplatin;
adjusted HR 0.43, 95 % CI 0.20–0.92; p = 0.029)
[Table 2] and the Q-ITT population [2]. Survival with-
out grade 4 toxicity and survival without clinically
important grade 3 or 4 toxicity were also significantly
improved in the pemetrexed ? carboplatin treatment
arm for all age subgroups (Table 2). The magnitude of
the HR change favoring pemetrexed ? carboplatin was
greater for the C70-year age group than for the\70-year
age group with respect to survival without grade 4 tox-
icity and survival without clinically important grade 3 or
4 toxicity (Table 2).
3.3 Efficacy
Among elderly patients, there were no statistically signif-
icant between-treatment group differences in overall sur-
vival (OS) or progression-free survival (PFS) [Table 2].
The median values were similar across all age-group sub-
sets. The HRs were similar for all age-group subsets except
for the C70-year age group, which favored pemetr-
exed ? carboplatin to a greater extent (Table 2). The
tumor response rate favored the pemetrexed ? carboplatin
arm across all age groups and, similarly to OS and PFS, the
magnitude of benefit increased for the elderly subsets
(Table 2).
3.4 Safety
Fewer PCb-treated patients experienced C1 drug-related
Grade 3 or 4 treatment-emergent adverse event (TEAE)
than DCb-treated patients (C65/C70) (PCb, 54.3 %/
58.8 %; DCb, 81.8 %/85.0 %; p = 0.020/p = 0.136), but
the proportions of patients experiencing C1 drug-related
TEAE of any grade were similar (\70/C65/C70): (PCb,
79.8 %/88.6 %/82.4 %; DCb, 90.6 %/87.9 %/90.0 %;
p = 0.056/p = 1.000/p = 0.644). Discontinuations due to
possibly drug-related serious AEs occurred in two C65-
year-old patients in each arm (pemetrexed ? carboplatin: 1
anemia and 1 decreased platelet count; docetaxel ? car-
boplatin: 2 febrile neutropenia) and in one C70-year-old
patient in each arm (pemetrexed ? carboplatin: anemia;
docetaxel ? carboplatin: febrile neutropenia). Notably,
there were no on-therapy deaths in either treatment arm in
elderly patients, patients aged \70 years, or the Q-ITT
population.
In patients aged C65 years, there were significantly
lower incidences of all-grade drug-related neutropenia,
leukopenia, febrile neutropenia, alopecia, and diarrhea in
the pemetrexed ? carboplatin arm than in the doce-
taxel ? carboplatin arm (Table 3). Docetaxel ? carbo-
platin-treated patients aged C65 years may be more likely
to suffer febrile neutropenia than the docetaxel ? carbo-
platin-treated Q-ITT population. Additionally, in patients
aged C65 years, the incidences of grade 3 or 4 neutropenia,
leukopenia, and febrile neutropenia were significantly
lower in the pemetrexed ? carboplatin arm.
In general, the between-arm trends and incidences of
possibly drug-related treatment-emergent AEs were similar
in patients aged C65 years and the Q-ITT population.
There were some differences within the C70-year age
group, perhaps because of the small sample size. None-
theless, regardless of treatment, elderly patients may be
more likely to suffer diarrhea, constipation, abdominal pain
(except in docetaxel ? carboplatin-treated patients
C70 years), and mucosal inflammation than patients aged
\70 years and the Q-ITT population (Table 3).
A summary of dose reductions due to AEs in the safety
population age-group subsets (\70 years, C65 years, and
C70 years) demonstrated that significantly more patients in
the docetaxel ? carboplatin arm than in the pemetr-
exed ? carboplatin arm had at least one dose reduction due
to AEs: pemetrexed ? carboplatin 9.0, 2.9, and 5.9 %,
respectively; docetaxel ? carboplatin 23.5, 39.4, and
40.0 %, respectively; p = 0.013, 0.001, and 0.023,
respectively). Notably, this difference was driven pre-
dominantly by neutropenia in the docetaxel ? carboplatin
arm, which led to at least one dose reduction due to an AE
significantly more often in each of the age-group subsets:
pemetrexed ? carboplatin 2.2, 0.0, and 0.0 %, respec-
tively; docetaxel ? carboplatin 17.6, 24.2, and 25.0 %,
respectively; p \ 0.001, 0.002, and 0.050, respectively).
3.5 Post-Discontinuation Anti-Cancer Therapy
Within the \70-, C65-, and C70-year age-group subsets,
62.9, 40.0, and 17.6 % of pemetrexed ? carboplatin-trea-
ted patients, respectively, and 48.2, 48.5, and 55.0 % of
docetaxel ? carboplatin-treated patients, respectively,
received post-study therapy. Among the Q-ITT patients,
55.7 % of pemetrexed ? carboplatin-treated patients and
49.5 % of docetaxel ? carboplatin-treated patients
received post-discontinuation therapy [2]. Within the\70-,
C65-, and C70-year age-group subsets, the most common
post-discontinuation chemotherapeutic agent used in
pemetrexed ? carboplatin-treated patients was docetaxel
(used in 23.6, 11.4, and 5.9 %, respectively), and in
docetaxel ? carboplatin-treated patients it was pemetrexed
(14.1, 12.1, and 15.0 %, respectively). Within the \70-,























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































294 J. R. Pereira et al.
C65-, and C70-year age-group subsets, post-study epider-
mal growth factor receptor tyrosine kinase inhibitors were
received by 22.5, 14.3, and 11.8 % of pemetrexed ? car-
boplatin-treated patients, respectively, and by 28.2, 27.3,
and 20.0 % of docetaxel ? carboplatin-treated patients,
respectively. Post-study radiotherapy was received by 21.3,
8.6, and 0.0 % of pemetrexed ? carboplatin-treated
patients, respectively, and by 22.4, 21.2, and 25.0 % of
docetaxel ? carboplatin-treated patients, respectively.
4 Discussion and Conclusion
Retrospective studies suggest that elderly patients can
receive a clinical benefit from platinum-based chemother-
apy similar to that seen in younger patients; toxicity may
be increased in this population but is still generally
acceptable. Nevertheless, physicians still hesitate to use
these regimens in elderly patients [7, 8]. Mortality rates for
elderly patients with lung cancer have increased over the
decades [9]. This could be partly related to lower chemo-
therapy usage in the elderly [10].
We performed a retrospective analysis of elderly patient
subsets (aged C65 and C70 years) within a phase III trial
evaluating pemetrexed ? carboplatin and doce-
taxel ? carboplatin in advanced nonsquamous NSCLC [2].
Elderly patients treated with pemetrexed ? carboplatin
tolerated slightly higher dose intensities and experienced
fewer dose reductions than elderly patients treated with
docetaxel ? carboplatin. The benefits of pemetr-
exed ? carboplatin were maintained in elderly patients
with advanced NSCLC. As seen in the Q-ITT population
and the \70-year age group, elderly pemetrexed ? car-
boplatin-treated patients experienced longer survival
without toxicity than docetaxel ? carboplatin-treated
patients did. There were no statistically significant
between-treatment arm differences in OS, PFS, or the
response rate among elderly patients, among patients aged
\70 years, and in the Q-ITT population; however, the
response rate was numerically higher in pemetr-
exed ? carboplatin-treated patients than in doce-
taxel ? carboplatin-treated patients, and the between-arm
response differences appeared greater in elderly patients
than in the those aged\70 years and the Q-ITT population.
This might be a reflection of greater variability due to the
smaller number of patients in the C70-year age group.
The retention of pemetrexed ? carboplatin-related
benefits in elderly patients is likely due to this regimen’s
favorable AE profile. Elderly patients treated with
pemetrexed ? carboplatin experienced lower rates of most
hematological AEs (i.e., neutropenia, leukopenia, lym-
phopenia, febrile neutropenia) than elderly patients treated
with docetaxel ? carboplatin. Moreover, there were
reduced rates of alopecia and diarrhea among elderly
patients treated with pemetrexed ? carboplatin. In both
arms, the AE trends in the elderly mostly mirrored those of
the Q-ITT population and the \70-year age group.
Importantly, there were no unexpected AEs in either
treatment arm, nor were there on-study deaths among
elderly patients. The between-arm toxicity profile differ-
ence was consistent across all age-group subsets. There
was a slight increase in selected toxicities (mucosal
inflammation, diarrhea, neutropenia, and leukopenia) in the
elderly age groups compared with the \70-year age-group
subset, regardless of the treatment arm. This may have
contributed to the improved survival without grade 4 tox-
icity and survival without grade 3 or 4 clinically important
toxicity differences observed with respect to the magnitude
of the HR in favor of pemetrexed ? carboplatin.
Subset analyses of pemetrexed registration trials showed
that the benefit of pemetrexed is maintained in elderly
advanced NSCLC patients without compromising tolera-
bility [11, 12]. In elderly first-line NSCLC patients treated
with pemetrexed ? cisplatin, the rates of neutropenia,
thrombocytopenia, and febrile neutropenia appeared to
increase with age [11]. However, in all age groups, the
\70-year age group, the C65-year age group, and C70-
year age group in our trial, the rates of neutropenia (39.6,
38.2, 45.7, and 47.1 %, respectively), thrombocytopenia
(14.2, 14.6, 14.3, and 11.8 %, respectively), and febrile
neutropenia (0, 0, 0, and 0 %, respectively) were approx-
imately the same in pemetrexed-treated patients. Differ-
ences between trials could possibly be attributed to the use
of carboplatin; however, this seems unlikely because car-
boplatin is associated with lower rates of nausea, vomiting,
and nephrotoxicity, but a higher rate of thrombocytopenia,
relative to cisplatin [5, 6].
In this exploratory analysis, defining C65 years as
‘elderly’ allowed for sufficient patient numbers to be
included in the main subgroup. Further analysis of C70-
year-old patients showed efficacy and safety similar to
those in C65-year-old patients, but the former was limited
by a small population size, yielding more variable results.
Our study underscores that NSCLC patients, regardless of
age, benefit from appropriate treatment [13], and supports
the idea that treatment selection in the elderly should not be
based solely on chronological age.
This exploratory analysis suggests that the outcomes of
elderly patients with nonsquamous NSCLC are consistent
with those in the \70-year age group and the Q-ITT pop-
ulation with respect to dose intensity, efficacy, and toler-
ability. Therefore, with few limitations, elderly patients
with advanced nonsquamous NSCLC and good perfor-
mance status should be treated similarly to younger
patients. We and others have shown that platinum-based
doublet therapy is a tolerable, viable option for elderly
Elderly Subset Analysis of an NSCLC Phase III Trial 295
advanced NSCLC patients [11, 12, 14]. However, our
conclusions are hypothesis generating, as this retrospective
analysis had a small sample size and unbalanced between-
arm patient characteristics. The limitations of retrospective
elderly patient studies include potential differences
between chronological age and medical fitness, elderly
population heterogeneity, arbitrary age cut-offs, and age-
associated co-morbidities. Our selection criteria of fit
elderly patients may not have been applicable to the gen-
eral elderly population. Therefore, a prospective clinical
trial involving a carefully controlled group of elderly
patients is warranted.
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